Best Biotech ETFs for 2026

Biotech ETFs give investors access to one of the most innovative and potentially rewarding corners of the healthcare sector. Biotechnology companies develop cutting-edge therapies including gene editing, mRNA platforms, immunotherapy, and rare disease treatments that can generate enormous returns when clinical trials succeed. However, the binary nature of drug development — where a single FDA decision can send a stock soaring or crashing — makes diversification through ETFs particularly valuable.

IBB from iShares is the benchmark biotech ETF, tracking the Nasdaq Biotechnology Index with a market-cap-weighted approach that tilts toward large, established biotech firms like Amgen, Gilead, and Vertex. XBI from SPDR takes an equal-weight approach, giving smaller clinical-stage biotechs equal footing with industry giants, which creates a higher-risk, higher-reward profile. ARKG, the ARK Genomic Revolution ETF, is actively managed by ARK Invest and focuses on genomics and genetic therapies, offering a more concentrated bet on the future of precision medicine.

Biotech investing requires patience and a strong stomach for volatility. The sector can underperform for extended periods during risk-off environments or when drug pipelines disappoint, but breakthroughs in areas like obesity treatments, cell therapy, and AI-driven drug discovery continue to create massive opportunities for the companies — and ETFs — positioned to benefit.